Liquids Containing Suspended Glass Particles

• US 20080026066A1
• Filed: 04/13/2005
• Published: 01/31/2008
• Est. Priority Date: 04/13/2004
• Status: Abandoned Application

• Current Assignee: Nova Bio-Pharma Technologies Limited
• Original Assignee: Cambridge Biostability Limited (Nova Bio-Pharma Holdings Ltd.)
• Inventors: ROSER, Bruce Joseph
• Application Number:
  US10/599,928
• Publication Number:
  US 20080026066A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/292 Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C12N 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Present proposals to use perfluorocarbons as a medium to suspend glass particles presents the problem of aggregation of the particles within the suspending medium. Overcoming this problem requires careful particle sizing and density matching techniques. An additional disadvantage of the large scale use of perfluorocarbons is their contribution to global warming. The inventor has realised that by replacing perfluorocarbons with the more environmentally friendly fluorinated ethers such as hydrofluoroethers or hydrofluoropolyethers a long lasting suspension of glass particles can be achieved without the need for such rigorous particle sizing or density matching processes.

Claims

1. A formulation comprising an active ingredient preserved in glassy or amorphous particles, the particles being suspended in a liquid in which at least one component comprises a hydrofluoroether, perfluroether, hydrofluroamine, perfluoroamine, hydrofluorothioether, perfluorothioether hydrofluoropolyether, perfluorpolyether or a general formula

R1-X—

R2 or

R1-X-(CF2Y)n(CF2CF2Z)m-R2 or

R1-[(X—

CF—

R2)n-(X—

CF2)m]OR3

where X, Y and Z are defined as O (oxygen), and ether, NR3 (N=nitrogen), an amine or S (sulphur); and

each of R1, R2 and R3 are defined as a non-fluorinated, partially fluorinated or fully fluorinated alkyl, cycloalkyl, aryl or arylalkyl group or an organic functional group, halogen group or cyano group.

2. A formulation according to claim 1 in which the particles contain a sugar glass or a glass which is a mixture of sugar, metal carboxylate, amino acid or calcium phosphate or any combination of these.

3. A formulation according to claim 1 in which the particles have a density which is matched to the density of the liquid sufficiently closely that the particles will remain in suspension under normal conditions.

4. A formulation according to claim 1 in which the liquid contains different components specified in claim 1 mixed in proportions to give a required density.

5. A formulation according to claim 1 in which the liquid contains a perfluorocarbon mixed with one or more components specified in claim 1.

6. A formulation according to claim 1 in which the active ingredient is a vaccine.

7. A formulation according to claim 1 in which the particles are made by spray drying.

8. A formulation according to claim 1 in which the particles are made by freeze drying.

9. A formulation according to claim 1 in which the particles are made by grinding.

10. A method of making a formulation according to claim 4 including the step of selecting liquids to give the required density matching properties and mixing them with the particles.

11. A formulation comprising an active ingredient preserved in glassy or amorphous particles, the particles being suspended in a liquid comprising a hydrofluoroether.